Brooke Chalmers
Medical · Maryville, TNNPI 1568811834
Payments from drug & device makers
Across 202 payments — averaging $19.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$610
- AbbVie$582
- Johnson & Johnson$353
- Alkermes, Inc.$327
- Otsuka America Pharmaceutical, Inc.$264
- Vanda Pharmaceuticals Inc.$247
- plus $2K from 14 others
What the payments were for
- Food & beverage$3,88898%
- Education$742%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 24 | $610 |
| AbbVie | 35 | $582 |
| Johnson & Johnson | 22 | $353 |
| Alkermes, Inc. | 18 | $327 |
| Otsuka America Pharmaceutical, Inc. | 16 | $264 |
| Vanda Pharmaceuticals Inc. | 8 | $247 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $245 |
| Lundbeck LLC | 13 | $229 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $215 |
| Teva Pharmaceuticals USA, Inc. | 9 | $163 |
| Axsome Therapeutics, Inc. | 8 | $153 |
| Novo Nordisk | 2 | $131 |
| Bausch Health US, LLC | 7 | $111 |
| E.r. Squibb & Sons, L.L.C. | 5 | $92 |
| Sunovion Pharmaceuticals Inc. | 4 | $68 |
| Almatica Pharma LLC | 3 | $58 |
| Eisai Inc. | 3 | $40 |
| Jazz Pharmaceuticals Inc. | 2 | $28 |
| Adlon Therapeutics L.p. | 1 | $24 |
| Tris Pharma Inc | 1 | $20 |
How this compares
$3,962 in reported general payments places this provider in the 80th percentile of 480 medical providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 13 | $101,614 |
| VraylarCariprazine Hcl | 18 | $27,640 |
| RexultiBrexpiprazole | 11 | $23,922 |
| TrintellixVortioxetine Hydrobromide | 29 | $18,041 |
| Chlorpromazine Hcl | 24 | $13,738 |
| Paliperidone ErPaliperidone | 62 | $12,987 |
| Quetiapine Fumarate | 318 | $9,239 |
| Fluvoxamine Maleate ErFluvoxamine Maleate | 16 | $8,390 |
| NamzaricMemantine Hcl/Donepezil Hcl | 12 | $7,507 |
| Fluphenazine Hcl | 12 | $6,435 |
| Olanzapine OdtOlanzapine | 13 | $3,929 |
| Ziprasidone Hcl | 17 | $2,990 |
| Trazodone Hcl | 226 | $2,942 |
| Oxcarbazepine | 50 | $2,800 |
| Vilazodone Hcl | 21 | $2,523 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $610 | $101,61413 claims |
| AbbVieVraylar, Namzaric | $582 | $35,14730 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $264 | $23,92211 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $245 | $18,04129 claims |
| Almatica Pharma LLCSertraline Hcl | $58 | $1,489186 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 480 medical providers in Tennessee.
Other medical in Maryville
- Chelsey HenryMaryville$5K
- Maria WoodChattanooga$130K
- Alyssa JamesonFranklin$65K
- Melissa LambertHendersonville$47K
- Stephanie HowardKnoxville$18K
- Evan HatfillNashville$18K
- Meredith McDanielChattanooga$17K
- Janet BreedingKnoxville$15K
- Paul MabenKnoxville$13K
- Hannah KirkGreeneville$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.